Previous 10 | Next 10 |
Shares of Blueprint Medicines (NASDAQ: BPMC) fell nearly 21% today after the company announced that its lead drug candidate, avapritinib, failed an important late-stage study in gastrointestinal stromal tumors (GIST). The experimental therapy didn't lead to an improvement in progression-free...
NeuBase Therapeutics (NASDAQ: NBSE ) -15% on equity offering . More news on: NeuBase Therapeutics, Inc., Yield10 Bioscience, Inc., Blueprint Medicines Corporation, Stocks on the move, , Read more ...
Blueprint Medicines (NASDAQ: BPMC ) slumps 15% premarket in reaction to its announcement that a Phase 3 clinical trial, VOYAGER , evaluating lead candidate avapritinib, branded as Ayvakit, in patients with unresectable/metastatic gastrointestinal stromal tumor (GIST) failed to...
CAMBRIDGE, Mass. , April 28, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced top-line results from the Phase 3 VOYAGER clinical trial of avaprit...
Deals and Financings AkesoBio [HK:9926], a Zhongshan developer of novel mono- and bi-specific antibodies, staged a $335 million Hong Kong IPO and climbed 50% higher in its first trading session. The company's general strategy is to develop bispecific antibodies using a PD-1 antibody as a bac...
Amid widespread uncertainty in healthcare around COVID-19 impact, Baird is focusing on clinical catalysts that continue to power biotech picks - and in particular it's declaring fresh picks on two stocks with data forthcoming. More news on: Constellation Pharmaceuticals, Inc., Blueprint Me...
Shares of Deciphera Pharmaceuticals ( DCPH ) have risen by 20% since my August 2019 update called the stock a Buy based on ripretinib's impressive showing in fourth-line and fourth-line plus gastrointestinal stromal tumors (GIST). Targeted oncology has been one of my favored themes to capita...
Systemic mastocytosis - overview Source: Blueprint Systemic mastocytosis [SM] is characterized by an excessive buildup of mast cells, typically, in the bone marrow or skin. Mast cells mediate inflammatory responses. There are five variants of SM which are grouped in two: Indolent sys...
Blueprint Medicines (NASDAQ: BPMC ) announces a pipeline update including topline data from the Phase 1/2 ARROW study evaluating pralsetinib (BLU-667) in patients with solid tumors. More news on: Blueprint Medicines Corporation, Healthcare stocks news, Read more ...
CAMBRIDGE, Mass. , April 1, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced the achievement of key milestones reflecting portfolio-wide pro...
News, Short Squeeze, Breakout and More Instantly...
Blueprint Medicines Corporation Company Name:
BPMC Stock Symbol:
NASDAQ Market:
Blueprint Medicines Corporation Website:
2024-05-13 18:15:03 ET Stephens analyst issues OVERWEIGHT recommendation for BPMC on May 13, 2024 04:31PM ET. BPMC was trading at $108.05 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 6 - Buy, 3 - Hold ...
2024-05-09 15:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
A look at the top 10 most actives in the United States Jaguar Health Inc. (JAGX) rose 30.3% to $0.2932 on volume of 173,918,707 shares Emergent Biosolutions Inc. (EBS) rose 71.0% to $3.3 on volume of 150,987,238 shares PROSHARES TRUST (SQQQ) fell 3.6% to $11.78 on volume of 136,332,744 sh...